Viela Bio collaborates with Hansoh Pharma to develop and commercialize inebilizumab for autoimmune diseases and hematologic cancers in China
“Our collaboration with Hansoh Pharma strengthens our ability to commercialize inebilizumab throughout the world,” commented Bing Yao, Ph.D., Viela’s Executive Chairman and Chief Executive Officer. “Their significant commercial,